OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer

NCT05949021 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer (TNBC)

Interventions

DRUG: Combination of liposomal doxorubicin

Sponsor

Mridula George, MD